Summary
Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung BL Reflex assay, a validating test for the diagnosis of lung cancer. The company’s molecular diagnostic products are based on its proprietary methylation technology, which is based on biological phenomenon called DNA methylation. Epigenomics’ development pipeline also comprises tests for monitoring, screening, diagnosis and prognosis assessment of colorectal and lung cancer. It offers services from basic research to product development, validate DNA methylation (epigenetic) biomarkers and support for obtaining regulatory approvals. Epigenomics is headquartered in Berlin, Germany.
Epigenomics AG (ECX) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Epigenomics AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Epigenomics AG, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Epigenomics AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Epigenomics AG, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Epigenomics AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Epigenomics AG, Medical Equipment, Deal Details 11
Partnerships 11
Biochain Institute Enters into Licensing Agreement with Epigenomics 11
Epigenomics And BioChain Expand Licensing Agreement For Septin9 11
Biochain Institute Enters Into Licensing Agreement With Epigenomics For Septin9 12
Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab For Septin9 Biomaker 13
Epigenomics Announces Option Licensing Agreement With QIAGEN 14
Epigenomics Enters Into Research Licensing Agreement With QIAGEN 15
Epigenomics Enters Into Commercialization Agreement With Polymedco For Epi proColon 16
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 17
Equity Offering 18
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 18
Epigenomics Raises USD5.6 Million in Rights Offering of Shares 19
Epigenomics Raises USD5.3 Million in Private Placement of Shares 19
Epigenomics Completes Private Placement Of Shares For US$4.5 Million 21
Epigenomics Announces Private Placement Of Shares For US$1.3 Million 21
Epigenomics Completes Rights Issue Of Common Stock For US$6 Million 22
Epigenomics Completes Private Placement Of Shares For US$0.7 Million 24
Debt Offering 25
Epigenomics Announces Private Placement Of Bonds For US$6.7 Million 25
Epigenomics AG - Key Competitors 27
Key Employees 28
Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 09, 2016: Epigenomics Announces 2016 Third Quarter and Nine Months Financial Results and Reports on Operational Highlights 30
Aug 10, 2016: Epigenomics Announces 2016 Second Quarter and Six Months Financial Results and Reports on Operational Highlights 32
May 23, 2016: Epigenomics Announces 2016 First Quarter Financial Results and Reports on Operational Highlights 33
Mar 18, 2016: Epigenomics Reports Results for the Financial Year Ended December 31, 2015 and Provides Outlook for 2016 34
Corporate Communications 36
Jun 30, 2016: Supervisory Board of Epigenomics appoints Gregory Hamilton as Chief Executive Officer (CEO) 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
Epigenomics AG, Medical Equipment, Key Facts, 2015 1
Epigenomics AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Epigenomics AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Epigenomics AG, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Epigenomics AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Epigenomics AG, Deals By Market, 2011 to YTD 2017 9
Epigenomics AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Biochain Institute Enters into Licensing Agreement with Epigenomics 11
Epigenomics And BioChain Expand Licensing Agreement For Septin9 11
Biochain Institute Enters Into Licensing Agreement With Epigenomics For Septin9 12
Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab For Septin9 Biomaker 13
Epigenomics Announces Option Licensing Agreement With QIAGEN 14
Epigenomics Enters Into Research Licensing Agreement With QIAGEN 15
Epigenomics Enters Into Commercialization Agreement With Polymedco For Epi proColon 16
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 17
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 18
Epigenomics Raises USD5.6 Million in Rights Offering of Shares 19
Epigenomics Raises USD5.3 Million in Private Placement of Shares 19
Epigenomics Completes Private Placement Of Shares For US$4.5 Million 21
Epigenomics Announces Private Placement Of Shares For US$1.3 Million 21
Epigenomics Completes Rights Issue Of Common Stock For US$6 Million 22
Epigenomics Completes Private Placement Of Shares For US$0.7 Million 24
Epigenomics Announces Private Placement Of Bonds For US$6.7 Million 25
Epigenomics AG, Key Competitors 27
Epigenomics AG, Key Employees 28
Epigenomics AG, Subsidiaries 29
List of Figures
Epigenomics AG, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
Epigenomics AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
Epigenomics AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
Epigenomics AG, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
Epigenomics AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Epigenomics AG, Medical Equipment, Deals by Type, 2011 to YTD 2017 7
Epigenomics AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Epigenomics AG, Medical Equipment, Deals by Market, 2011 to YTD 2017 9
